EUVIMEDEUVIMED entdecken
Crossref

Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data

Sarmad Sadeghi iD, Primo N Lara iD, Andrea Necchi iD, Parkash S Gill, Thomas W Flaig iD, Seth P Lerner iD, Monish Aron, Siamak Daneshmand iD

JCO Oncology Practice · 2026

DOI: 10.1200/op-25-00464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2026. Verfasst von Sarmad Sadeghi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medicine, and Urology Departments, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Neoadjuvant cisplatin-based chemotherapy before radical cystectomy (RC) has been standard-of-care treatment for muscle-invasive bladder cancer (MIBC) for over two decades. The study aimed to explore the outcomes of systemic therapy for MIBC. METHODS A cohort analysis of patients treated with RC for MIBC across the United States was performed using the National Cancer Database. The primary outcome measure was overall survival (OS), defined as the time from the date of initial diagnosis to the date of death from any cause. Additional variables including patient characteristics, pathologic complete response (pCR), clinical complete response (cCR), surgical margins, and the impact of surgical volume were also explored. RESULTS Between 2006 and 2021, 47,983 patients who underwent RC for MIBC were included: 14,730 (31%) received neoadjuvant systemic therapy before RC. With a median follow-up of 82 months, the median OS was 61.1 months (95% CI, 59.3 to 62.59). Pathologic T0 and downstaging to ≤pT2 were associated with improved OS. Immunotherapy monotherapy was 55%-66% less likely to induce a pCR but was associated with improved OS compared with multiagent chemotherapy. Treatment at facilities at 90th+ percentile of surgical volume was associated with improved OS. Neoadjuvant systemic therapy was associated with improved OS compared with adjuvant systemic therapy. CONCLUSION These results support the use of neoadjuvant systemic therapy and underscore that in addition to pT0, ypTis carcinoma in situ (CIS) and ypT1 are associated with improved OS. Perioperative systemic therapy maybe more effective before rather than after surgery. Future studies should focus on whether patients with no evidence of muscle-invasive disease (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCarcinoma, Transitional CellHumansFemaleMaleAgedNeoadjuvant TherapyMiddle AgedCystectomyNeoplasm InvasivenessPathologic Complete Response

Autor:innen und Institutionen

  • Medicine, and Urology Departments, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA.
  • Hematology-Oncology, Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA.
  • Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Medicine University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA.
  • Medicine, University of Colorado School of Medicine, Aurora, CO.

ORCID-Profile: Sarmad Sadeghi, Primo N Lara, Andrea Necchi, Thomas W Flaig, Seth P Lerner, Siamak Daneshmand

Zitieren

APA

Sadeghi, S., Lara, P. N., Necchi, A., Gill, P. S., Flaig, T. W., Lerner, S. P., Aron, M., & Daneshmand, S. (2026). Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data. JCO Oncology Practice. https://doi.org/10.1200/op-25-00464

Vancouver

Sadeghi S, Lara PN, Necchi A, Gill PS, Flaig TW, Lerner SP, et al. Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data. JCO Oncology Practice. 2026. doi:10.1200/op-25-00464

BibTeX
@article{Sadeghi2026,
  author = {Sadeghi, Sarmad and Lara, Primo N and Necchi, Andrea and Gill, Parkash S and Flaig, Thomas W and Lerner, Seth P and Aron, Monish and Daneshmand, Siamak},
  title = {Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-25-00464}
}
Kostenlos starten →